713 completed, 138 recruiting, 133 unknown, 128 terminated. 1280 Phase 2, 181 Phase 1, 132 Phase 3.
Follow Neurocognitive Disorders: new trials by email Literature Review of Neurocognitive Disorders trials Research Report on Neurocognitive Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Terazosin for Dementia With Lewy Bodies Terazosin Hydrochloride, Placebo - Dementia With Lewy Bodies | Phase 1 / Phase 2 | Not yet recruiting | Qiang Zhang | 40 | 2027-10-01 | 2026-03-12 |
| AV-1959R Vaccine in Individuals With Preclinical Alzheimer's Disease AV-1959R, Placebo - Preclinical Alzheimer's Disease, Alzheimer Disease | Phase 2 | Not yet recruiting | Institute for Molecular Medicine | 160 | 2027-10-01 | 2026-10-21 |
| Terazosin And Metabolic Engagement in Alzheimer's Disease Terazosin (Hytrin), Placebo - Alzheimer s Disease | Phase 2 | Not yet recruiting | Qiang Zhang | 100 | 2027-08-01 | 2026-09-01 |
| Remotely Administered tDCS to Improve Cognitive Function in Veterans With mTBI and PTSD Principal Investigator Transcranial direct current stimulation (tDCS), Cognitive training - Cognition, Brain Injuries | Phase 2 | Not yet recruiting | VA Office of Research and Development | 46 | 2027-05-24 | 2026-02-17 |
| A Basket Clinical Study to Assess Glycerol Tributyrate in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like Episodes (MELAS) or Leber's Hereditary Optic Neuropathy-Plus (LHON-Plus) Glycerol Tributyrate - MELAS Syndrome, Lebers Hereditory Optic Neuropathy With Extra Ocular Symptoms (LHON-Plus) | Phase 1 / Phase 2 | Not yet recruiting | George Washington University | 24 | 2027-03-01 | 2026-10-05 |
| The Dose Finding Study of DAOIB Added to tDCS for AD DAOIB - Transcranial Direct Current Stimulation, Dementia | Phase 2 | Suspended | Chang Gung Memorial Hospital | 140 | 2027-01-01 | 2026-03-20 |
| NMDA Enhancement Combined With Omega-3 for Early Dementia DAOIB+Omega-3, DAOIB+Placebo - Omega 3 Fatty Acids, Dementia | Phase 2 | Not yet recruiting | Chang Gung Memorial Hospital | 140 | 2027-01-01 | 2026-10-22 |
| Intranasal Oxytocin Intervention for Caregivers to Persons With Dementia Placebo, Oxytocin Intranasal Spray 12 International Unit (12IU), Oxytocin Intranasal Spray 24 International Unit (24IU) - Stress | Phase 2 | Recruiting | University of Nebraska | 32 | 2026-12-20 | 2026-11-02 |
| Peer Support for Family Caregivers of Older Adults Living With Dementia Peer Support, Usual Care - Caregiver Burden, Caregiver Burnout | Phase 2 | Not yet recruiting | Ohio State University | 344 | 2026-12-01 | 2026-10-14 |
| Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin Psilocybin, Cognitive Training - Alzheimer's Disease | Phase 2 | Recruiting | National Institute on Aging (NIA) | 200 | 2026-11-09 | 2026-11-04 |
| Alzheimer's Tau Platform: Regimen A - AADvac1 AADvac1, Donanemab - Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease | Phase 2 | Enrolling by invitation | Paul S. Aisen | 450 | 2026-11-03 | 2026-10-26 |
| A Nutritional and Pharmacological Intervention for Body, Brain, and Longevity Effects (NIBBLE) FMD1 (LNT22-017-1), Rapamycin, Placebo - Cerebral Blood Flow, APOE 4 | Phase 1 / Phase 2 | Not yet recruiting | Cedars-Sinai Medical Center | 60 | 2026-11-01 | 2026-09-16 |
| Restoring Vascular and Insulin Function To Augment Anti-Amyloid Therapy in Alzheimer's Disease Empagliflozin, Insulin, Insulin Placebo - Alzheimer Disease | Phase 2 | Not yet recruiting | Wake Forest University Health Sciences | 30 | 2026-11-01 | 2026-09-30 |
| A Phase 2 Clinical Study of Simenafil Hydrochloride Tablets in the Treatment of Alzheimer's Disease Simenafil Hydrochloride Tablets 2.5 mg, Simenafil Hydrochloride Tablets 5 mg, Simenafil Hydrochloride Tablets 10 mg - Alzheimer Disease | Phase 2 | Not yet recruiting | Vigonvita Life Sciences | 200 | 2026-11-01 | 2026-10-29 |
| Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease RO7568282, Placebo - Alzheimer's Disease | Phase 2 | Not yet recruiting | Hoffmann-La Roche | 450 | 2026-10-31 | 2026-10-07 |
| A Phase 2b/3 Clinical Study Evaluating T3D-959 in Mild-to-Moderate Alzheimer's Disease Subjects T3D-959, Placebo Comparator - Alzheimer's Disease | Phase 2 / Phase 3 | Not yet recruiting | T3D Therapeutics, Inc. | 376 | 2026-10-26 | 2025-05-09 |
| A Trial of ALN-6457 in Adult Participants With Symptomatic Prion Disease (PrD) ALN-6457 - Prion Disease | Phase 1 / Phase 2 | Not yet recruiting | Regeneron Pharmaceuticals | 60 | 2026-10-23 | 2026-09-22 |
| A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of NIO752 in Primary Tauopathies NIO752, Placebo - Progressive Supranuclear Palsy, Corticobasal Degeneration | Phase 2 | Not yet recruiting | Novartis Pharmaceuticals | 48 | 2026-10-23 | 2026-10-09 |
| Post-acute Infectious Syndrome - Aripiprazole Symptom Evaluation (PAIS-AriSE) Aripiprazole (low-dose, 1mg), Placebo - Post-acute Infectious Syndrome (PAIS), Post-COVID-19 Condition (PCC or Long COVID) | Phase 2 | Not yet recruiting | Christiana Franke | 138 | 2026-10-01 | 2026-07-20 |
| Study of Intracerebroventricular Injections of Autologous Adipose-Derived Stem Cells (RB-ADSCs) in Participants With Mild-Moderate Alzheimer's Disease RB-ADSC, Placebo - Alzheimer Disease | Phase 2 | Not yet recruiting | Regeneration Biomedical, Inc. | 115 | 2026-10-01 | 2026-08-26 |
Showing 20 of 1280. Sign in to see all of them.
Alzheimer Disease (713) · Cognitive Dysfunction (364) · Dementia (227) · Huntington Disease (76) · Delirium (53) · Cognition Disorders (47) · Neurodegenerative Diseases (40) · Lewy Body Disease (37) · Central Nervous System Diseases (36) · Frontotemporal Dementia (35) · Brain Diseases (33) · Emergence Delirium (33) · Memory Disorders (32) · Mental Disorders (29)
Mental Disorders (1251) · Nervous System Diseases (1077) · Brain Diseases (962) · Central Nervous System Diseases (959) · Neurodegenerative Diseases (836) · Dementia (721) · Tauopathies (700) · Cognition Disorders (432) · Pathological Conditions, Signs and Symptoms (315) · Signs and Symptoms (239) · Neurologic Manifestations (225) · Neurobehavioral Manifestations (187) · Basal Ganglia Diseases (141) · Movement Disorders (137)
Donepezil (41) · Dexmedetomidine (24) · Sodium Chloride (22) · Saline Solution (19) · Memantine (17) · florbetapir (15) · Insulin (12) · Sugars (12) · 7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole (11) · Transcranial Direct Current Stimulation (11) · Cognitive Training (9) · Ketamine (9) · Levetiracetam (9) · Transcranial Magnetic Stimulation (9) · vanutide cridificar (9)
Pfizer (25) · Chang Gung Memorial Hospital (19) · Eli Lilly and Company (16) · Johns Hopkins University (16) · Avid Radiopharmaceuticals (13) · Columbia University (13) · Massachusetts General Hospital (13) · Novartis Pharmaceuticals (12) · GlaxoSmithKline (11) · Hoffmann-La Roche (10) · Merck Sharp & Dohme LLC (9) · VA Office of Research and Development (9) · Vanderbilt University Medical Center (9) · Wake Forest University Health Sciences (9) · Washington University School of Medicine (9)
United States (758) · Canada (158) · United Kingdom (128) · France (112) · Germany (112) · Spain (108) · Australia (91) · Netherlands (69) · Italy (68) · China (54) · Poland (52) · Japan (43) · South Korea (42) · Sweden (38) · Belgium (35)
Suzanne Craft, PhD (10) · Ilise Lombardo, MD (6) · Laura Gault, MD (5) · Adam Boxer, MD, PhD (4)
PMID 36463457, PMID 33974419, PMID 38489195, PMID 25918556, PMID 33189083, PMID 34532852, PMID 39800465, PMID 40603145, PMID 29480210, PMID 32250312, PMID 38706271, PMID 25669746, PMID 25731629, PMID 26967206, PMID 26967214, PMID 27494299, PMID 27756421, PMID 27871675, PMID 29854923, PMID 30558645, PMID 30755255, PMID 31353964, PMID 31381524, PMID 31710528, PMID 31969177, PMID 32107748, PMID 32410694, PMID 33417236, PMID 33646153, PMID 33973646, PMID 34366147, PMID 34521461, PMID 34570177, PMID 34687726, PMID 36627206, PMID 36811812, PMID 36934371, PMID 36946448, PMID 38599894, PMID 39166791, PMID 39350369, PMID 39513754, PMID 39974075, PMID 40009460, PMID 40120616, PMID 40235521, PMID 40368603, PMID 40667684, PMID 41220869, PMID 41804324
2023 (16), 2009 (14), 2014 (12), 2015 (10), 2016 (10), 2018 (6), 2025 (6), U01AG059798 (5), 2017 (4), R01AG046179 (4), U01AG042791 (4), 2008 (3), 2019 (3), K23AG052633 (3), R01AG050440 (3)